Bioactive Peptides and Derivatives as Therapeutic Agents: Potential Applications in Disease Treatment

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 3349

Special Issue Editor


E-Mail Website
Guest Editor
Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan
Interests: bioactive peptide; adrenomedullin; inflammatory bowel disease; COVID-19; hypertension
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bioactive peptides help to maintain equilibrium in organisms, and their imbalance is closely related to the development of pathological conditions. Relative or absolute deficiencies in bioactive peptides are observed in many diseases, and thus, their replenishment can improve disease outcomes. Historically, insulin is a bioactive peptide, and many derivatives of native insulin are currently used as therapeutic agents in diabetic patients. Peptide analogs of glucagon-like peptide (GLP-1) have been developed for the treatment of diabetes, and GLP-1 also shows benefit in the treatment of obesity and cardiovascular diseases and is currently being explored for Parkinson’s disease. The applications of bioactive peptides can be diverse and varied. Adrenomedullin and its related peptides were initially developed by many researchers, including our group, as therapeutic agents for cardiovascular diseases due to their strong vasodilative activity. However, their use in therapeutic indications is expanding further to inflammatory diseases such as inflammatory bowel disease and other conditions including sepsis, pneumonia, and COVID-19.

In this Special Issue, we cordially invite authors and investigators to submit original research or review articles pertaining to the use of bioactive peptides and derivatives, particularly their progressive applications and innovative possibilities as therapeutic agents for various diseases.

Dr. Toshihiro Kita
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive peptide
  • peptide modification
  • application
  • cardiovascular disease
  • inflammatory disease
  • digestive disease
  • neurological disease
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

26 pages, 3868 KiB  
Article
Antibacterial, Antifungal, and Cytotoxic Effects of Endophytic Streptomyces Species Isolated from the Himalayan Regions of Nepal and Their Metabolite Study
by Ram Prabodh Yadav, Chen Huo, Rabin Budhathoki, Padamlal Budthapa, Bibek Raj Bhattarai, Monika Rana, Ki Hyun Kim and Niranjan Parajuli
Biomedicines 2024, 12(10), 2192; https://doi.org/10.3390/biomedicines12102192 - 26 Sep 2024
Cited by 1 | Viewed by 2787
Abstract
Background/Objectives: Recently, antimicrobial-resistant pathogens and cancers have emerged as serious global health problems, highlighting the immediate need for novel therapeutics. Consequently, we aimed to isolate and characterize endophytic Streptomyces strains from the rhizospheres of the Himalayan region of Nepal and identify specialized metabolites [...] Read more.
Background/Objectives: Recently, antimicrobial-resistant pathogens and cancers have emerged as serious global health problems, highlighting the immediate need for novel therapeutics. Consequently, we aimed to isolate and characterize endophytic Streptomyces strains from the rhizospheres of the Himalayan region of Nepal and identify specialized metabolites with antibacterial, antifungal, and cytotoxic potential. Methods: To isolate Streptomyces sp., we collected two soil samples and cultured them on an ISP4 medium after pretreatment. We isolated and identified the strains PY108 and PY109 using a combination of morphological observations and 16S rRNA gene sequencing. Results: The BLAST results showed that PY108 and PY109 resembled Streptomyces hundungensis PSB170 and Streptomyces sp. Ed-065 with 99.28% and 99.36% nucleotide similarity, respectively. Antibacterial assays of ethyl acetate (EA) extracts from both isolates PY108 and PY109 in a tryptic soy broth (TSB) medium were conducted against four pathogenic bacteria. They showed significant antibacterial potential against Staphylococcus aureus and Klebsiella pneumoniae. Similarly, these extracts exhibited moderate antifungal activities against Saccharomyces cerevisiae and Aspergillus niger. Cytotoxicity assays on cervical cancer cells (HeLa) and breast cancer cells (MCF-7) revealed significant potential for both extracts. LC-MS/MS profiling of the EA extracts identified 27 specialized metabolites, including diketopiperazine derivatives, aureolic acid derivatives such as chromomycin A, and lipopeptide derivatives. In comparison, GC-MS analysis detected 34 metabolites, including actinomycin D and γ-sitosterol. Furthermore, a global natural product social molecular networking (GNPS)-based molecular networking analysis dereplicated 24 metabolites in both extracts. Conclusions: These findings underscore the potential of endophytic Streptomyces sp. PY108 and PY109 to develop new therapeutics in the future. Full article
Show Figures

Graphical abstract

Back to TopTop